scholarly journals Improved quality of life and joint functions in patients with knee rheumatoid arthritis who underwent five portal arthroscopic synovectomy

PeerJ ◽  
2018 ◽  
Vol 6 ◽  
pp. e4727 ◽  
Author(s):  
Wen-Xin Liu ◽  
Yao Jiang ◽  
Qing-Xiang Hu ◽  
Xie-Bo You
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Knee Joint ◽  
Class I ◽  
Arthroscopic Synovectomy ◽  
Pharmaceutical Therapy ◽  
Das 28 ◽  
Group A ◽  
One Year

Objectives To evaluate the outcomes of patients with rheumatoid arthritis (RA) of the knee who underwent five portal arthroscopic synovectomy, with or without post-operative negative pressure drainage (NPD). Material and Methods A prospective clinical trial was performed. Patients with class I, II, and III RA of the knee were enrolled. They underwent five portal arthroscopic synovectomy. Post-operatively, they received either NPD (group A) or non-NPD (group B). Health assessment questionnaire (HAQ), disease activity score 28 (DAS 28), and Lysholm knee joint score were evaluated before the operations, and at six weeks, three months, and one year after the operations. Results A total of 36 patients were enrolled into the study, with 63.9% (23) female patients and mean age of 47.2 years old. All of the patients had clinical symptoms (joint swelling, pain, and dysfunction) for at least six months with poor responses to the traditional pharmaceutical therapy. There were 12, 16, and eight patients in class I, II, and III RA groups, respectively (six IA, six IB, eight IIA, eight IIB, four IIIA, and four IIIB). One year after the operation, patients had statistically significant improvements on HAQ, DAS 28, and Lysholm knee joint scores. More improvements were observed in patients with class I diseases. There were no statistically significant differences between group A and B. Conclusion Five portal arthroscopic synovectomy could increase the quality of life, decrease disease activities, and improve joint functions in patients with RA. More benefits were observed in patients with early disease developments. Patients in the NPD group did not show more improvements compared to the patients in the non-NPD group.

THU0148 Quality of life and knee function of the patients with rheumatoid arthritis after arthroscopic synovectomy

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 205.2-205
Author(s):  
M. Lipina ◽  
M. Makarov ◽  
V. Amirdjanova ◽  
S. Makarov ◽  
V. Pavlov ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Knee Function ◽  
Arthroscopic Synovectomy

scholarly journals AB0278 REAL LIFE EXPERIENCE OF DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS TREATED WITH BIOLOGICAL DMARDS VERSUS TOFACITINIB.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1438.2-1438
Author(s):  
V. Boyadzhieva ◽  
N. Stoilov ◽  
E. Kurteva ◽  
R. Stoilov
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Activity Index ◽  
Real Life ◽  
Disease Activity Index ◽  
Significant Difference ◽  
One Year

Background:Assessment of disease activity and quality of life are one of the main indicators for determining the effectiveness of treatment with disease-modifying antirheumatic drugs. In recent years, a new group has entered the market - target synthetic DMARDS, which prove their effectiveness in treating RA comparable to that of biological products.Objectives:The aim of this study is to evaluate the disease activity and quality of life of patients with rheumatoid arthritis (RA) treated with biological agents in comparison with Tofacitinib (real life data from Bulgarian population) and determine whether or not the benefits of different therapies were sustained over a follow up period of 1 year.Methods:164 patients were selected with a mean age 55.34 ± 16SD years, meeting the 1987 ACR and /or ACR/ EULAR (2010) classification criteria for Rheumatoid arthritis (RA). Patients were arranged according to treatment regimens: Tocilizumab (TCL) 30 patients, Certolizumab (CZP) 16, Golimumab (GOL) 22, Etanercept (ETN) 20, Adalimumab (ADA) 20, Rituximab (RTX) 16, Infliximab (INF) 20, Tofacitinib (TOF) 20. Disease activity and quality of life was the primary concern. Independent joint assessor evaluated 28 joints on baseline, 6th and 12th month’s thereafter. CRP was used to measure the inflammatory process.DAS28-CRP, clinical disease activity index (CDAI) and simplified disease activity index (SDAI)were calculated. On baseline all of the patients’ groups had severe disease activity (mean DAS28-CRP > 5.2, mean CDAI > 22, mean SDAI > 26. The quality of life was evaluated via EQ-5D.All of the patients were on stable therapy according to the inclusion criteria, and didn’t interrupt any of the medications including biological or target synthetic treatment.Results:Significant clinical improvement and statistically significant reduction in disease activity were observed in patients treated with bDMARDS and tsDMARDS within 6 months (p <0.005) of treatment and after 12 months of follow-up (p=0.039). The mean value of DAS28-CRP after one year follow up showed an non-inferior effect of Tofacitnib (3.04± 0.81) in comparison to biological treatment (TCL: 3.07 ± 0.73; CZP: 3.06 ± 0.65; GOL: 2.49 ± 0.76; ETN: 2.85 ± 0.55; ADA: 3.15 ± 0.82; RTX: 2.90 ± 0.70; INF: 3.14; ± 0.61; TOF: 3.04± 0.81). An improvement was also observed for the 6 to 12 months of follow-up as we did not detect a significant difference in the activity of the disease assessed by CDAI among the different drug groups.The mean values showing the change of the SDAI over the study period also outline comparable profiles. All of the treatment groups achieved a rapid reduction in disease activity that continued to decrease through the 6 and 12 months period, respectively, as supported by changes in SDAI.The quality of life evaluated with EQ-5D revealed significant improvement on the 6-th month of follow up as well as after 12th month (p<0.005) without significant difference between the observed groups.Conclusion:Real-life data show that patients on biological treatment as well as those on Tofacitinib therapy achieve a significant decrease in disease activity after one year of follow-up. This gives us reason to accept the importance of non-inferior effect of jak-inhibitors and their place in treatment of Rheumatoid arthritis.Disclosure of Interests:Vladimira Boyadzhieva: None declared, Nikolay Stoilov: None declared, Ekaterina Kurteva: None declared, Rumen Stoilov Grant/research support from: R-Pharm

scholarly journals The Effect of Follow ups with Weekly Phone Calls on the Outcome and Quality of Life Among the Patients with Rheumatoid Arthritis

2021 ◽  
Vol 10 (3) ◽  
pp. 104-107
Author(s):  
Anusheh Haghighi ◽  
Maryam Dibadin ◽  
Alireza Farahani ◽  
Mohammad Amin Abbasi ◽  
Mohsen Arabi
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Therapeutic Process ◽  
Intervention Group ◽  
Phone Call ◽  
Control Group ◽  
Phone Calls ◽  
Das 28 ◽  
Severity Of The Disease

Background: The present study aimed at evaluating the effect of weekly phone calls on treatment outcomes and quality of life among a group of Iranian patients with rheumatoid arthritis (RA). Materials and Methods: In this randomized clinical trial study, 60 patients aged 15-85 with RA were randomly assigned to intervention and control groups. The intervention group, in addition to a monthly assessment on a weekly basis, received a full 3-month follow-up telephone conversation in order to follow the correct and regular use of the drug and respond to the patients’ questions. The control group was only evaluated routinely. Finally, the severity of the disease activity (based on DAS-28) and the quality of life (based on the SF-12 questionnaire) were evaluated after three months. Results: After three months from the onset of intervention, a significant reduction was observed in the number of tender joints, mean erythrocyte sedimentation rate (ESR), and total score of DAS-28 in the intervention group compared to the control group. In addition, after three months of treatment, the quality of life for the intervention group improved significantly more than that of the control group. Conclusion: A weekly phone call with the patients suffering from RA with the purpose to guide the therapeutic process and respond to the patients’ questions could positively improve the severity of the disease along with the quality of life among the patients.

scholarly journals Influence of balneophysical therapy on activity, functional capacity, and quality of life in patients with rheumatoid arthritis

2009 ◽  
Vol 137 (3-4) ◽  
pp. 171-174 ◽  
Author(s):  
Sonja Stojanovic ◽  
Aleksandar Dimic ◽  
Bojana Stamenkovic ◽  
Aleksandra Stankovic ◽  
Jovan Nedovic
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Functional Capacity ◽  
Mean Value ◽  
Disease Modifying Antirheumatic Drugs ◽  
Das 28 ◽  
Before And After ◽  
The Mean

Introduction It has been well known that balneophysical therapy has a therapeutic effect on clinical and biological parameters of disease activity in the patients with rheumatoid arthritis (RA). Objective. To determine the influence of balneophysical therapy on functional capacity, activity and quality of life of the patients with RA primarily treated with some of disease modifying antirheumatic drugs. Methods. The study enrolled 73 patients with RA treated with some of disease modifying antirheumatic drugs (Methotrexate in 85% of patients). During hospitalization at the Clinical Rheumatologic Department of the Institute 'Niska Banja', the patients were treated, beside the medicamentous therapy, by hydrotherapy (oligomineral, homeothermic, low radioactive water), mineral peloid therapy, electrotherapy and kinesiotherapy. Before and after balneotherapy, the patients filled in the Health Assessment Questionnaire (HAQ) and the Quality of Life Rheumatoid Arthritis (QOL-RA) scale. The Disease Activity Score (DAS) 28 was used to measure the disease activity before and after balneotherapy. A possible value of HAQ was from 0 to 3, and QOL-RA from 0 to 10. Results. The mean value of the duration of balneophysical therapy was 14.7?4.8 days. We found significant improvement of functional capacity in the patients with RA. The average HAQ score before balneotherapy was 1.07?0.61, and 0.86?0.55 after balneotherapy, which was statistically significantly lower (p<0.05). DAS 28 after balneotherapy was also statistically significantly lower than DAS 28 before balneotherapy: the mean value of DAS 28 before therapy was 6.30?0.81 and after therapy 5.48?0.75 (p<0.001). The quality of life significantly improved after balneophysical therapy: the mean value of QOL-RA scale before therapy was 5.38?1.62 and after therapy 7.35?1.81 (p<0.05). Conclusion. Balneophysical therapy, when properly dosed, is an effective, adjuvant therapy in the patients with RA of mild disease activity. Balneophysical therapy has a positive influence on disease activity, functional capacity and quality of life in the patients with rheumatoid arthritis.

Effectiveness of custom-made foot orthoses in patients with rheumatoid arthritis: a randomized controlled trial

2018 ◽  
Vol 33 (4) ◽  
pp. 661-669 ◽  
Author(s):  
María Reina-Bueno ◽  
María del Carmen Vázquez-Bautista ◽  
Sergio Pérez-García ◽  
Carolina Rosende-Bautista ◽  
Antonia Sáez-Díaz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Controlled Trial ◽  
Foot Orthoses ◽  
Foot Pain ◽  
Randomized Controlled ◽  
Custom Made ◽  
Group A ◽  
Group B

Objective: To determine the effect of custom-made foot orthoses versus placebo insoles on pain, disability, foot functionality, and quality of life. Design: Double-blinded randomized controlled trial. Setting: University Podiatric Clinical Area. Subjects: Patients with rheumatoid arthritis. Interventions: Patients were randomly assigned to either group A, which received custom-made foot orthoses, or group B, which received placebo, flat cushioning insoles, for three months. Main measures: The primary outcome was foot pain, measured by visual analog scale. Foot functionality, foot-related disability, and quality of life were measured using the Foot Function Index, the Manchester Foot Pain and Disability Index, and 12-Item Short Form Health Survey (SF-12) questionnaires, respectively, at the beginning and at days 30, 60, and 90. Results: A total of 53 patients, aged 59.21 ± 11.38 years, received either the custom-made foot orthoses ( N = 28) or the placebo ( N = 25). For the analysis of the data, only participants who had been measured at the four time points (0, 30, 60, and 90 days) were included. In group A, all variables showed statistically significant differences when comparing the initial and final measurements. Pain showed 6.61 ± 2.33 and 4.11 ± 2.66 in group A, at baseline and at 90 days, respectively, and Group B showed 6.16 ± 1.77 and 5.60 ± 2.71 at baseline and at 90 days, respectively. This was the only variable that showed statistically significant difference between groups ( P = 0.048). Conclusion: The custom-made foot orthoses significantly reduced the participants’ foot pain, although they did not have positive effects on disability, foot functionality, and quality of life compared with only cushioning.

scholarly journals Assessment of health-related quality of life in patients with rheumatoid arthritis and analysis of its change during csDMARDS and bDMARDS therapy after one year of follow-up

2019 ◽  
pp. 29-43
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Biological Treatment ◽  
Systemic Autoimmune Disease ◽  
Sf 36 ◽  
Related Quality ◽  
Health Related ◽  
One Year

Rheumatoid arthritis is a chronic disabling systemic autoimmune disease of the musculoskeletal system, which significantly impairs the quality of life of patients. The aim of this study is to evaluate the quality of life of patients with RA using standardized HAQ-DI, SF-36, EQ-5D, RAQoL questionnaires and analyze its change after one year of treatment with conventional synthetic and biological medical products. For the purpose of the study, 220 patients were selected and monitored. Of these, 96 patients were treated with csDMARDS divided into 5 groups and 124 patients treated with biological medicinal products divided into 6 groups. All patients completed the standardized questionnaires at the initial visit, at 6 and 12 months. The results are calculated using licensed calculators. A significant improvement in quality of life was observed in all groups of patients up to the 6th month of the follow-up period, after which, until the 12th month of follow-up, a significant improvement was observed only in those receiving biological treatment evaluated by HAQ-DI, SF-36 and EQ-5D. In contrast to the results obtained with the other three indicators (HAQ, SF-36, EQ-5D) for patients treated with csDMARDS, the RAQоL score in the disease-specific questionnaire showed a significant improvement in their quality of life from 6 months to 12 months (p = 0.009).

Sign in / Sign up

Export Citation Format

Share Document